Letter: Response to Cost-per-Responder Analysis of Tralokinumab Versus Dupilumab for Moderate-to-Severe Atopic Dermatitis Across Universal Health Care Systems

Dermatitis · Published 2026-04-17 · DOI 10.1177/17103568261441048

Authors being retrieved — see the publisher record. https://doi.org/10.1177/17103568261441048

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Letter: Assessing Information and Misinformation About Diaper Dermatitis Treatment on TikTok · Dermatitis · 2026 · Same journal
Prospective Cohort Study: Hexyl-2,5-Diaminobenzoate Is a Hypoallergenic Alternative for Patients With Allergic Contact Dermatitis to Para-Phenylenediamine · Dermatitis · 2026 · Same journal
Allergic Contact Dermatitis to Isopropyl Alcohol: An Overlooked Cause of Postprocedural Dermatitis · Dermatitis · 2026 · Same journal
Exploring a STAT6–STAT3 Anatomical Immune Divergence Model in Atopic Dermatitis: Implications for Dupilumab Responsiveness and Adult Scabies Sparing · Dermatitis · 2026 · Same journal
Fragrance in Dermatology: Revisiting Sensitization and Clinical Use · Dermatitis · 2026 · Same journal
Letter : Pediatric Atopic Dermatitis and Symptoms of Cognitive Impairment · Dermatitis · 2026 · Same journal
Letter: Disparities in Patch Testing for Allergic Contact Dermatitis: Insights From a National Electronic Health Record Dataset · Dermatitis · 2026 · Same journal
Letter: Generalized Lichen Pigmentosus Triggered by Orthopedic Osteosynthesis Material · Dermatitis · 2026 · Same journal
Systemic Allergic Dermatitis Induced by Nickel Leaching from a Stainless Steel Bottle Containing a Citric Acid Solution · Dermatitis · 2026 · Same journal
Practical Techniques: Photopatch Testing · Dermatitis · 2026 · Same journal